Neurocrine’s $2.9 Billion Bet: A Strategic Move Into Rare Diseases In a major move that could reshape its future, Neurocrine Biosciences has…
Eli Lilly Bets Big on Obesity Treatment With $3.5 Billion Pennsylvania Plant
4 Mins read
Eli Lilly is doubling down on its push to dominate the fast-growing obesity drug market. The pharmaceutical giant announced plans to invest…
Patent Expiries Trigger Deal Frenzy as Drugmakers Turn to Biotech M&A
4 Mins read
Global pharmaceutical giants are accelerating efforts to acquire biotech companies and late-stage drug assets as the industry braces for a looming “patent…
Inside the $5.3 Billion Obesity Drug Deal: Roche and Zealand Pharma's Bold Move to Rival Novo Nordisk and Eli Lilly
3 Mins read
Roche and Zealand Pharma’s $5.3 Billion Gambit: A Game-Changer for Obesity Treatment In a major move in the world of pharmaceuticals, Roche…
